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Cardiovascular diseases are the most common cause of mortality 
and morbidity in most populations. As the traditional modifiable 
risk factors (smoking, hypertension, dyslipidemia, diabetes 
mellitus, and obesity) were defined decades ago, we decided to 
analyze recent data in patients who survived acute coronary 
syndrome (ACS). The Czech part of the study included data from 
999 males, and compared them with the post-MONICA study 
(1,259 males, representing general population). The Lithuanian 
study included 479 male patients and 456 age-matched controls. 
The Kazakhstan part included 232 patients and 413 controls. 
In two countries, the most robust ACS risk factor was smoking 
(OR 3.85 in the Czech study and 5.76 in the Lithuanian study), 
followed by diabetes (OR 2.26 and 2.07) and hypertension 
(moderate risk elevation with OR 1.43 and 1.49). These factors 
did not influence the ACS risk in Kazakhstan. BMI had no 
significant effect on ACS and plasma cholesterol was surprisingly 
significantly lower (P<0.001) in patients than in controls  
in all countries (4.80±1.11 vs. 5.76±1.06 mmol/l in Czechs;  
5.32±1.32 vs. 5.71±1.08 mmol/l in Lithuanians; 4.88±1.05 vs.  
5.38±1.13 mmol/l in Kazakhs/Russians). Results from our study 
indicate substantial heterogeneity regarding major CVD risk 
factors in different populations with the exception of plasma total 
cholesterol which was inversely associated with ACS risk in all 
involved groups. These data reflect ethnical and geographical 
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The etiology of atherosclerotic coronary disease 
is multifactorial. Aside from non-modifiable risk factors 
such as age, being male and genetic predisposition, many 
other risk factors could be managed by changes to 
individual life style and/or pharmacotherapy. More than 




200 of these risk factors have been described (Hopkins 
and Williams 1981), of which the most important are 
considered to be high plasma cholesterol level, 
hypertension, diabetes mellitus, smoking and overweight/ 
obesity. The definition of these risk factors was assessed 
decades ago and is originally based on data obtained from 
the Framingham study (Dawber et al. 1962). Data are 
available on the prevalence and changes of these risk 
factors in European populations thanks to the MONICA 
and post-MONICA studies (Keil 2005, Cifkova et al. 
2010, Lindroth et al. 2014, Vikhireva et al. 2014), but 
much less evidence is available regarding the real pattern 
of risk factors in patients suffering from cardiovascular 
diseases (CVD). 
In order to estimate further development in 
mortality and morbidity on CVD, it is of substantial 
importance to be aware of the prevalence of the 
traditional risk factors both in healthy populations and in 
patients with CVD. 
We analyzed traditional CVD risk factors in four 
populations of males with acute coronary syndrome 
(ACS) from Prague, Czech Republic, Kaunas, Lithuanian 
Republic and Astana, Kazakhstan and compared them 





We collected data in three completely 
independent centers. 
In the Czech group, 999 male patients (younger 
than 65 years) hospitalized between 2006 and 2012 at the 
coronary care unit of the Institute for Clinical and 
Experimental Medicine for acute coronary syndrome 
(ACS) (Hubáček et al. 2015, Hubáček et al. 2016) were 
included. As a controls, we used a 1 % sample of the 
general population from the WHO MONICA study 
(MONItoring of CArdiovascular diseases (Tunstall-Pedoe 
et al. 2003) in 9 Czech regions) and a survey from 
2000/2001 (1,259 males) was included. 
In the Lithuanian group, 479 patients with ACS 
were enrolled in the study. The mean age of the patients 
was 59.9±11.0 years, all of whom were admitted to the 
Department of Cardiology of the Lithuanian University of 
Health Sciences Hospital between 2007 and 2011. 
The control group consisted of 456 males free 
from symptoms of IHD and stroke, matching the study 
group design according to age. The control group 
consisted of subjects from a random sample of the 
Kaunas population screened within the international 
HAPPIE (Health, Alcohol and Psychosocial factors In 
Eastern Europe) project (Peasey et al. 2006), the CINDI 
(Countrywide Integrated Non-communicable Disease 
Intervention) project (Grabauskas et al. 2008) and the 
“Kaunas Healthy Ageing Study”. 
In the Kazakhstan group, 232 male patients 
(aged 50-74 years) hospitalized between 2013 and 2015 
at the coronary care unit of the Astana City Hospital #2 
for acute coronary syndrome were included in the 
analysis. 
For the Kazakhstan control group, the study 
sample was randomly selected from registries of all 
inhabitants at local outpatient clinics. Persons in the age 
range 50-74 year were included. A total number of 
416 male adults were used in the current analysis, 
excluding those who self-reported diagnosed CVD in  
the history (Supiyev et al. 2015, Supiyev et al. 2016). 
Excluded were also subjects with serious diseases 
(cancers, renal failure). In total, there were 63.7 % of 
Kazakhs, 24.9 % of Russians with 12.4 % declaring the 
others ethnicities. 
At all centre’s, the patients completed 
a questionnaire and their lipoprotein parameters were 
measured in the local laboratory within 24 h of the onset 
of symptoms. ACS was defined according to the standard 
criteria based on clinical symptoms, ECG findings and 
cardiac-enzyme abnormalities. 
The studies were performed in agreement with 
The Code of Ethics of the World Medical Association 
(Declaration of Helsinki) for experiments involving 
humans. All patients signed informed consent before they 
were included in the study. 
 
Definition of risk factors 
Basic/traditional risk factors were defined as 
follows: 1) current or past smokers; 2) body mass index 
(BMI) ≥25 kg/m2; 3) hypertension (self-reported and/or 
antihypertensive treatment and/or blood pressure over 
139/89; and 4) diabetes as self-reported diabetes and/or 
antidiabetic (also dietary) treatment. Both in controls and 
in patients, data were obtained from personal 
questionnaires completed under the supervision of 
a trained nurse prior to discharge. Diagnoses were 
determined by coronary care unit physicians, during 
which time anthropometric and biochemical parameters 
were reviewed. 
Cholesterol and triglycerides (in fasting plasma, 
day after admission) were assessed using conventional 
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enzymatic methods (reagents from Boehringer Mannheim 
Diagnostics and Hoffmann-La Roche). 
 
Statistical analyses 
Data from questionnaires and biochemical 
parameters were entered into the database. Statistical 
analysis was performed using standard statistical tests as 
follows: chi square test for categorical variables and 
ANOVA for continuous variables. As the study is 
focused on confirmation of the traditional CVD risk 
factors, no multivariate analysis has been performed. For 
adjustment purposes, we used ANCOVA for continuous 
variables and logistic regression for discrete variables. 
Odds ratios (OR) and 95 % confidence intervals (CI) 






We collected complete data from 999 males 
(93.2 % out of 1,072 hospitalized patients fulfilled the 
basal criteria; 55 refused to participate; and in the case of 
18 patients, data were incomplete) with ACS. Controls 
were slightly but significantly (P<0.001) younger than 
patients (Table 1). 
The largest difference between patients and 
controls was observed with regard to prevalence of 
smoking. Among the patients, only 14.9 % were never 
smokers, in comparison to 40.3 % in the general 
population (P<0.0001; OR (95 % CI) 3.85 (3.12-4.73)). 
The second major risk was associated with  
the prevalence of diabetes – there were twice as many 
diabetics (P<0.0001; 2.26 (1.76-2.91)) in patients 
(17.8 %) than in controls (8.9 %). 
With regard to hypertension, a significant 
difference was observed only in the unadjusted model, but 
not after adjustment for age. Prevalence of overweight was 
almost identical between patients and controls. 
Plasma cholesterol levels were significantly 
lower (P<0.001) in patients (4.80±1.11 mmol/l) than in 
controls (5.76±1.06 mmol/l). This difference remained 
significant even after the exclusion of patients (13.4 % 




This part of the study included 479 patients and 
456 age matched controls (Table 2) and observations 
revealed similar results to those obtained in the Czech 
patient/control branch. 
This part further underlines the importance of 
smoking as a major risk factor of ACS. Among the 
patients, 28.4 % were never smokers, in comparison to 
64.1 % in the general population (P<0.0001), which 
means that the OR (95 % CI) associated with smoking 
was 5.76 (3.78-6.75). 
Diabetes (OR 2.13, 95 % CI 1.22-3.73) was the 
second most important risk factor, more than doubling 
the increase of risk. 
Similar to the Czech data, hypertension 
(OR 1.49, 95 % CI 1.03-2.16) had only a minor effect 
(but still significant at P=0.04) and body weight had no 
effect (P=0.76). 
Finally, total plasma cholesterol was also  
here significantly lower (P<0.001) in patients  
(5.32±1.32 mmol/l) than in controls (5.71±1.08 mmol/l). 
 
Kazakhstan branch 
Within the Kazakhstan subjects, the risk of 
myocardial infarction was not associated with any 
traditional risk factor (Table 3). The proportion of 
diabetes and obesity were even slightly higher among 
controls in the Kazakhstan group, and the hypertension 
and smoking were more prevalent in patients, but there 
were not statistically significant differences between the 
groups. 
The difference between total cholesterol levels 
was in the similar direction (P<0.001) like in other two 
countries (Table 3). Surprisingly, the differences remain 
significant (P<0.05) even after dividing the group 
according the ethnicity – among Kazakhs, controls 
(N=267) had cholesterol 5.34±1.19 mmol/l and cases 
(N=138) 4.77±1.03 mmol/l, and among Russians the 
values were 5.43±1.04 mmol/l for controls (N=89) vs. 




Our study analyzed the prevalence of the five 
most commonly examined risk factors of cardiovascular 
disease among males suffering from ACS. Some of our 
results are surprising, especially the (absence of) 
association of the total cholesterol and acute forms of 
ischemic heart disease. 
 
 




Table 1. Prevalence of traditional risk factors among Czech males with acute coronary syndrome and controls. 
 
 Patients Controls P P# 
N 999 1,259   
Age (years) 54.7 ± 8.0 49.0 ± 10.8 0.001 - 
Total cholesterol (mmol/l) 4.80 ± 1.11 5.76 ± 1.06 0.001 0.001 
Total cholesterol* (mmol/l) 4.89 ± 1.13 5.75 ± 1.06 0.001 0.001 
Triglycerides (mmol/l) 2.06 ± 1.49 1.97 ± 1.28 n.s. 0.02 
Triglycerides* (mmol/l) 2.03 ± 1.47 1.94 ± 1.24 n.s. 0.02 
Ever smokers (%) 85.1 59.7 0.00001 0.0001 
Diabetes (%) 17.8 8.9 0.0005 0.01 
Hypertension (%) 50.6 41.6 0.001 n.s. 
Overweight (%)  80.1 79.9 n.s. n.s. 
Statin treatment (%) 13.4 8.0 0.005 - 
 




Table 2. Prevalence of traditional risk factors among Lithuanian males with acute coronary syndrome and controls. 
 
 Patients Control group P value 
N 479 456  
Age (years) 59.9 ± 11.0 59.1 ± 10.6 0.27 
Total cholesterol (mmol/l)  5.32 ± 1.32 5.71 ± 1.08 0.0001 
Triglycerides (mmol/l) 1.74 ± 1.60 1.34 ± 0.77 0.0001 
Ever smokers (%) 71.6 35.9 0.0001 
Diabetes (%) 10.6 6.8 0.005 
Hypertension (%) 82.3 74.6 0.05 
Overweight (%) 77.7 76.8 0.76 




Table 3. Prevalence of traditional risk factors among Kazakhstan males (63.7 % Kazakhs and 24.9 % Russians included) with acute 
coronary syndrome and controls. 
 
 Patients Control group P value 
N 232 416  
Age (years) 59.9 ± 6.9 60.6 ± 7.3 0.27 
Total cholesterol (mmol/l) 4.88 ± 1.05 5.38 ± 1.13 0.001 
Triglycerides (mmol/l) 1.65 ± 0.83 1.65 ± 1.32 0.995 
Ever smokers (%) 74.2 69.7 0.224 
Diabetes (%) 12.6 14.2 0.555 
Hypertension (%) 59.4 53.1 0.127 
Overweight (%) 74.9 78.9 0.250 
Statin treatment (%) 7.1 9.0 0.63 
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It seems that only two risk factors for acute 
forms of ischemic heart disease are now considered 
important. These are: smoking and diabetes mellitus. Our 
study showed that smoking status was the most extreme 
factor, as only about 20 % of all patients consisted of 
never smokers and, based on our results, smokers are 
about five times more likely to experience ACS than 
never smokers. Surprisingly, in Kazakhstan, these factors 
have not been associated with CVD risk. 
The two other risk factors, namely hypertension 
and overweight/obesity, seemed to be of less importance. 
This is underlined by the fact that both factors were not 
significantly associated with ACS after adjustment for 
age in Czech Republic or Kazakhstan and that only 
a borderline significance was observed in the Lithuanian 
population. From the MONICA study, it is clear that the 
prevalence of hypertension in the general population is 
now lower than it was (Dawber et al. 1962, Cifkova et al. 
2010, Lindroth et al. 2014, Vikhireva et al. 2014). As 
a consequence of the success of primary prevention, we 
detected relatively low differences in hypertension 
prevalence between patients and controls. However, this 
finding needs to be further interpreted very carefully. 
There was a higher prevalence of individuals treated with 
antihypertensive drugs in patients than in controls. 
Furthermore, as our blood pressure values were obtained 
on the second day of hospitalization, it is possible that 
they do not exactly reflect the values before the onset of 
ACS. 
Also, based on the analysis of the prevalence of 
overweight, controls were not leaner than patients. 
The most interesting finding was that ACS 
patients had lower plasma total cholesterol than controls, 
independently in all three different countries. This was 
valid even after exclusion of patients and controls on 
hypolipidemic treatment, and after adjustment for age. 
One of explanations is that plasma total cholesterol is 
going down as a consequence of acute myocardial 
infarction. Studies have detected a decrease of about 7 % 
of total cholesterol after the onset of ACS (Wattanasuwan 
et al. 2001, Fresco et al. 2002). In a Czech branch, where 
we have for the majority of subjects both cholesterol 
values at admission and from fasting blood sampling, the 
identical decrease was obtained (Staněk et al. 2016). In 
this study, the total cholesterol values at admission were 
nonsignificantly lower than in age matched controls 
(Staněk et al. 2016). If we assume that the effect in all 
our populations is identical, then total plasma cholesterol 
would still not be a risk factor for cardiovascular disease, 
as expected. 
Second explanation is unique role of LDL 
cholesterol and not total cholesterol. Unfortunately, 
calculating (using the Friedewald formula) precise values 
of LDL cholesterol in ACS patients through the 
hospitalization are not reliable. One of reasons is 
possibility that heparinization (as a standard approach in 
pre-hospital ACS patients care) results in a decrease of 
plasma triglyceride levels (Mulder et al. 1993) due to 
hydrolysis of TG-rich lipoprotein particles. This could 
also modify LDL levels in not well predictable manner. 
In the literature, the fact that total plasma 
cholesterol levels are lower in patients with ACS/MI is 
often “hidden” and not clearly presented. Other 
publications (for example see Pérez-Hernández et al. 
2012) have confirmed the risk associated with 
dyslipidemia, but not with plasma total cholesterol. 
Dyslipidemia is defined as abnormal values of total 
plasma/LDL cholesterol, HDL cholesterol and 
triglycerides. In most subjects, in fact, elevated plasma 
TG values are the reason of dyslipidemia. As prevalence 
of obesity and diabetes mellitus is increasing, elevated 
plasma triglycerides and associated lipid disorders (small 
atherogenic LDL particles, remnant lipoprotein particles) 
are becoming the essence of atherogenic dyslipidemia. 
Similarly, in our two populations, TG values were 
significantly higher in patients than in controls. In 
agreement with this finding, plasma TG values, rather 
than plasma TC values are predictors of total mortality 
(Hubáček 2015, Liu et al. 2013, Pikhart et al. 2015, Piťha 
et al. 2015). 
Even the global INTERHEART study recognize 
as risk factor of myocardial infarction the high 
ApoB/ApoA1 ratio, which was considered to be superior 
to commonly used cholesterol derived values and ratios 
(Mc Queen et al. 2008), one of reasons was that not all 
samples have been available after fasting status, 
reflecting to certain extent also settings of our study. 
It should be noted that our results are not  
unique (Morales-Suarez-Varela et al. 2011, Nikolajević-
Starčević and Petrovič 2013). In fact, some other recent 
studies have recorded similar results, questioning the 
health risks associated with elevated plasma cholesterol 
levels, especially in the case, if they have been focused 
on the mortality data. For example, a study by 
Tamosiunas et al. (2014) presented the results from the 
Lithuanian MONICA and HAPIEE studies and concluded 
that CVD mortality was not associated with plasma 
cholesterol in males or in females and that plasma 




cholesterol below 5.2 mmol/l was associated with 
enhanced risk of CVD. Also, values of adjusted hazard 
ratios obtained from the NHANES III study point to the 
insignificance of plasma cholesterol levels in cases where 
cardiovascular or total mortality was analyzed (Yang 
et al. 2012). Based on their results, researchers from the 
HUNT2 study (Petursson et al. 2012) even concluded 
that plasma cholesterol levels should be omitted from 
cardiovascular risk calculation. Similarly, the Seoul Male 
Cohort Study (Kim et al. 2013) found that cholesterol 
was not associated with CVD mortality and, finally, 
a study of almost 100 000 Chinese subjects found no 
effect of plasma cholesterol on cardiovascular or total 
mortality (Liu et al. 2014). It should be noted that these 
studies also did not confirm the risks associated with 
higher BMI values.  
Thus, we can conclude that the importance of 
total plasma cholesterol as a discriminating risk factor of 
CVD is becoming less and less important at least at the 
population level and other lipid parameters – mainly 
triglycerides and possibly LDL and/or non-HDL 
cholesterol are of importance. This may also be further 
supported by the fact that, first, plasma levels of lipids 
have significantly declined over recent decades for about 
20 % of the general population (Cífková et al. 2010); 
therefore, a much higher proportion of the population 
now corresponds to recommended values. A further 
explanation could be linked to the role played by higher 
levels of remnant lipoprotein particles and their 
cholesterol content, which are not detected in the fasting 
state (Varbo et al. 2013, Varbo et al. 2015), but which are 
reflected in higher plasma triglycerides. 
Despite the continuous decline in cardiovascular 
mortality since 2000 in all EU countries, CVD is still 
responsible for almost 40 % of deaths in these countries 
(OECD 2016). Despite the refinement of the ACS criteria 
(Thygesen et al. 2012), no significant development has 
been observed over the last forty years in relation to the 
definition of CVD risk factors. For example, the selection 
of risk factors is based on the Framingham offspring 
study (Dawber et al. 1962). But the population’s 
prevalence for most of these CVD risk factors (as defined 
more than a half of the century) has significantly changed 
(Keil 2005, Cifkova et al. 2010, Lindroth et al. 2014, 
Vikhireva et al. 2014). We strictly keep to the “big five”, 
while failing to acknowledge the prevalence and 
importance for these factors to rise in some cases 
(smoking and diabetes) and decline in others (BMI and 
plasma cholesterol). 
As a consequence, estimating CVD risk might 
be misleading when based on total plasma cholesterol 
levels as the main risk factor. Even though we are aware 
of the limitations of this cross-sectional study, similar 
findings from our three independent centers, along with 
further published studies, allow us to propose a more 
cautious approach to the development of algorithms 
based on cardiovascular risk factors established decades 
ago. New prospective studies are definitely needed to 
confirm this important change in traditional 
cardiovascular risk factors. 
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